β3Gn-T9 Activators
Forskolin is known for its ability to raise intracellular cAMP levels, which subsequently activates PKA and can lead to an enhanced phosphorylation state within the cell, a condition that may favor the activity of β3Gn-T9. Epigallocatechin Gallate (EGCG) and Genistein bring about their effects through multifarious pathways; while EGCG has a broad influence on signaling molecules and pathways, Genistein specifically inhibits tyrosine kinases, both culminating in a cellular state that can promote the function of β3Gn-T9. Similarly, small molecule inhibitors like LY294002, Rapamycin, SB203580, PD98059, and SP600125 target crucial kinases and regulatory proteins, effectively creating a domino effect within the signaling networks that can propagate to enhance the biological activity of β3Gn-T9.
Ionomycin elevates intracellular calcium, a key secondary messenger in numerous signaling cascades, which can activate calcium-dependent proteins and possibly result in upregulated β3Gn-T9 activity. In contrast, Sodium Butyrate and 5-Azacytidine exert their influence by altering the epigenetic landscape, with Sodium Butyrate inhibiting histone deacetylases and 5-Azacytidine interfering with DNA methylation. These modifications can lead to a more transcriptionally active chromatin state, potentially increasing the expression of the β3Gn-T9 gene. Dibutyryl-cAMP (db-cAMP), a synthetic analog of cAMP, can mimic the effects of endogenous cAMP and activate PKA, thereby fostering a cellular environment that supports β3Gn-T9 activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Elevates cAMP, which can activate PKA leading to phosphorylation events that modify the cellular environment and increase β3Gn-T9 activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
Affects various signaling pathways and could enhance the expression of genes related to the function of β3Gn-T9. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
As a tyrosine kinase inhibitor, it can modulate signaling pathways that indirectly upregulate β3Gn-T9's function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3K, altering AKT signaling and potentially affecting the molecular processes governing β3Gn-T9 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can change protein synthesis and folding pathways that may enhance the stability or activity of β3Gn-T9. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that could shift the balance of cellular signaling, indirectly promoting β3Gn-T9 activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Increases intracellular calcium, potentially affecting calcium-dependent signaling mechanisms that regulate β3Gn-T9. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A MEK inhibitor that may alter ERK pathway signaling, potentially influencing regulatory mechanisms of β3Gn-T9. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 19 | |
A histone deacetylase inhibitor that can lead to chromatin remodeling and increased expression of genes including those for β3Gn-T9. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
Induces DNA demethylation, which could result in increased expression of the β3Gn-T9 gene. | ||||||